{"id":"https://openalex.org/W1983250356","doi":"https://doi.org/10.1016/j.jalz.2013.04.166","title":"O2\u201306\u201303: ACU\u2010193: A candidate therapeutic antibody that selectively targets soluble beta\u2010amyloid oligomers","display_name":"O2\u201306\u201303: ACU\u2010193: A candidate therapeutic antibody that selectively targets soluble beta\u2010amyloid oligomers","publication_year":2013,"publication_date":"2013-07-01","ids":{"openalex":"https://openalex.org/W1983250356","doi":"https://doi.org/10.1016/j.jalz.2013.04.166","mag":"1983250356"},"language":"en","primary_location":{"id":"doi:10.1016/j.jalz.2013.04.166","doi":"https://doi.org/10.1016/j.jalz.2013.04.166","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jalz.2013.04.166","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2013.04.166","source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2013.04.166","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081926493","display_name":"Grant A. Krafft","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Grant Krafft","raw_affiliation_strings":["Acumen Pharmaceuticals, Inc., Livermore, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals, Inc., Livermore, California, United States","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054270816","display_name":"Franz F. Hefti","orcid":"https://orcid.org/0000-0002-1177-2714","observed_orcids":["https://orcid.org/0000-0002-1177-2714"]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Franz Hefti","raw_affiliation_strings":["Acumen Pharmaceuticals, Inc., Livermore, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals, Inc., Livermore, California, United States","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078101395","display_name":"William F. Goure","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Goure","raw_affiliation_strings":["Acumen Pharmaceuticals, Inc., Livermore, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals, Inc., Livermore, California, United States","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079115898","display_name":"Jasna Jerec\u0131\u0300\u0107","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jasna Jerecic","raw_affiliation_strings":["Acumen Pharmaceuticals, Inc., Livermore, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals, Inc., Livermore, California, United States","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111687574","display_name":"Kent Iverson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kent Iverson","raw_affiliation_strings":["Acumen Pharmaceuticals, Inc., Livermore, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals, Inc., Livermore, California, United States","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041163981","display_name":"Patricia Ann Walicke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patricia Walicke","raw_affiliation_strings":["Acumen Pharmaceuticals, Inc., Livermore, California, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals, Inc., Livermore, California, United States","institution_ids":["https://openalex.org/I4210160595"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210160595"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":null,"fwci":0.3609,"has_fulltext":true,"cited_by_count":11,"citation_normalized_percentile":{"value":0.51241019,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"9","issue":"4S_Part_8","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11266","display_name":"Neuroinflammation and Neurodegeneration Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6023800373077393},{"id":"https://openalex.org/C2776156579","wikidata":"https://www.wikidata.org/wiki/Q417667","display_name":"Amyloid beta","level":3,"score":0.5814372301101685},{"id":"https://openalex.org/C2777633098","wikidata":"https://www.wikidata.org/wiki/Q2736051","display_name":"Amyloid (mycology)","level":2,"score":0.5185226202011108},{"id":"https://openalex.org/C2777807558","wikidata":"https://www.wikidata.org/wiki/Q4914764","display_name":"Biodistribution","level":3,"score":0.4996070861816406},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4876164495944977},{"id":"https://openalex.org/C2776925932","wikidata":"https://www.wikidata.org/wiki/Q1755122","display_name":"Neurodegeneration","level":3,"score":0.463418185710907},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.45834681391716003},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.43939095735549927},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.43791529536247253},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4235311448574066},{"id":"https://openalex.org/C12554922","wikidata":"https://www.wikidata.org/wiki/Q7100","display_name":"Biophysics","level":1,"score":0.3877050280570984},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.32628172636032104},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2732508182525635},{"id":"https://openalex.org/C2779281246","wikidata":"https://www.wikidata.org/wiki/Q172847","display_name":"Peptide","level":2,"score":0.23160862922668457},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.208279550075531},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20295023918151855},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.19939354062080383},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.15757957100868225},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.07880988717079163},{"id":"https://openalex.org/C179104552","wikidata":"https://www.wikidata.org/wiki/Q11165","display_name":"Inorganic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jalz.2013.04.166","doi":"https://doi.org/10.1016/j.jalz.2013.04.166","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jalz.2013.04.166","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2013.04.166","source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jalz.2013.04.166","doi":"https://doi.org/10.1016/j.jalz.2013.04.166","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jalz.2013.04.166","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.jalz.2013.04.166","source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's & Dementia","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1983250356.pdf","grobid_xml":"https://content.openalex.org/works/W1983250356.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2980997982","https://openalex.org/W2114358369","https://openalex.org/W2960149900","https://openalex.org/W4367296309","https://openalex.org/W4312086451","https://openalex.org/W2008752021","https://openalex.org/W4390193045","https://openalex.org/W1994898376","https://openalex.org/W2766981357","https://openalex.org/W4207003846"],"abstract_inverted_index":{"Soluble":[0],"beta-amyloid":[1,17,56,90,101,104,125,147,171,240,269],"oligomers":[2,91,102,126,172,270],"are":[3],"widely":[4],"recognized":[5],"as":[6,292],"the":[7,143,262,313,319],"key":[8],"molecular":[9],"pathogens":[10],"in":[11,127,142,173,177,195,243,255,271,339],"Alzheimer's":[12,37],"disease.":[13,38],"Because":[14],"these":[15],"non-fibrillar":[16],"assemblies":[18],"inhibit":[19],"synaptic":[20,121,251],"function,":[21],"trigger":[22],"early":[23],"memory":[24],"deficits":[25],"and":[26,58,84,106,109,136,154,180,192,199,214,252,265,288,290,304,318,348],"initiate":[27],"neurodegeneration,":[28],"they":[29],"represent":[30],"a":[31,45,68,293,340],"highly":[32],"attractive":[33],"intervention":[34],"target":[35,152],"for":[36,54,99,222,334],"In":[39,149],"this":[40],"presentation":[41],"we":[42],"describe":[43],"ACU-193,":[44],"promising":[46],"new":[47],"drug":[48],"candidate":[49],"with":[50,59,92,169],"high":[51],"binding":[52,114,122],"selectivity":[53,98],"soluble":[55,89,100,124,170,239,268],"oligomers,":[57],"potent":[60],"capability":[61],"to":[62,79,88,115,161,229,260,276,299],"block":[63],"their":[64],"synaptotoxicity.":[65],"ACU-193":[66,118,151,186,207,234,247,296],"is":[67,227,248,297,324,329],"humanized,":[69],"affinity":[70],"matured":[71],"IgG2":[72],"monoclonal":[73],"antibody":[74,205],"that":[75,321,331],"has":[76,208],"been":[77,220,274],"engineered":[78],"minimize":[80],"cellular":[81],"effector":[82],"functions":[83],"immunogenicity.":[85],"It":[86,328],"binds":[87],"low":[93],"nanomolar":[94],"affinity,":[95],"exhibits":[96],">500-fold":[97],"versus":[103],"monomer":[105],"fibrillic":[107],"beta-amyloid,":[108],"does":[110,139],"not":[111,140],"exhibit":[112],"cross-reactive":[113],"other":[116,203],"proteins.":[117],"potently":[119],"blocks":[120],"of":[123,145,202,233,267,280,315,344],"cultured":[128],"hippocampal":[129],"neurons":[130],"(IC":[131],"50":[132],"=":[133],"17":[134],"nM),":[135],"its":[137],"efficacy":[138,156,323,335],"diminish":[141],"presence":[144],"excess":[146],"monomer.":[148],"vivo":[150],"engagement":[153],"behavioral":[155,302,322],"were":[157],"demonstrated":[158],"by":[159],"administration":[160],"Tg-AD":[162],"mice,":[163,196],"which":[164],"afforded":[165],"dose-dependent":[166,189],"complex":[167,264],"formation":[168],"brain":[174,193,231],"tissue,":[175],"reduction":[176],"plaque":[178],"deposition,":[179],"significantly":[181],"reduced":[182],"abnormal":[183],"nocturnal":[184],"hyperactivity.":[185],"exhibited":[187],"linear,":[188],"pharmacokinetics,":[190],"biodistribution,":[191],"penetration":[194],"rats,":[197],"dogs,":[198],"monkeys,":[200],"typical":[201],"CNS-directed":[204],"drugs.":[206],"an":[209],"overall":[210],"excellent":[211],"safety":[212],"profile,":[213],"high-yielding,":[215],"stable":[216],"cell":[217],"lines":[218],"have":[219,273],"established":[221],"efficient":[223],"production.":[224],"Human":[225],"dosing":[226],"expected":[228,249,298],"deliver":[230,300],"levels":[232,242,266],">200-fold":[235],"higher":[236],"than":[237],"measured":[238],"oligomer":[241],"AD":[244,256],"CSF;":[245],"thus":[246],"improve":[250],"cognitive":[253],"function":[254],"patients.":[257],"Biomarker":[258],"assays":[259,283,317],"measure":[261],"drug-target":[263],"CSF":[272],"developed":[275],"support":[277],"clinical":[278],"studies":[279],"ACU-193.":[281],"These":[282],"should":[284],"allow":[285],"patient":[286],"selection":[287],"stratification":[289],"serve":[291],"companion":[294],"diagnostic.":[295],"acute":[301],"benefits":[303],"chronic":[305],"disease":[306],"modification":[307],"benefits.":[308],"Clinical":[309],"develop":[310],"plans":[311],"reflect":[312],"availability":[314],"biomarker":[316],"expectation":[320],"achieved":[325],"relatively":[326,345],"quickly.":[327],"anticipated":[330],"initial":[332],"evidence":[333],"will":[336],"be":[337],"obtained":[338],"phase":[341],"Ib":[342],"study":[343],"short":[346],"duration":[347],"cost.":[349]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}